Abstract: Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease (AD). As a multisystem disorder, it presents with a complex and heterogeneous clinical profile (Kalia and Lang, 2015). The hallmark motor symptoms include bradykinesia, resting tremor, muscular rigidity, and postural instability. In addition, PD encompasses a wide spectrum of nonmotor symptoms such as anosmia, rapid eye movement sleep behavior disorder, mood disturbances, and cognitive decline. As neurodegeneration progresses, patients experience a marked deterioration in quality of life, often resulting in long-term disability and a high degree of dependence on caregivers. Despite decades of research, available treatments for PD remain symptomatic, primarily aimed at restoring dopaminergic function or compensating for its loss. No disease-modifying therapies capable of halting or reversing neurodegeneration have yet been approved. This therapeutic gap has driven intensive efforts to develop novel strategies to block, slow, or reverse PD pathology. Among these, immunotherapeutic approaches have attracted increasing attention, inspired by recent advances in AD, with several monoclonal antibodies targeting amyloid-β now approved for clinical use.